论文部分内容阅读
目的分析TACE、PEI、PVC三介入联合治疗中晚期原发性肝癌的临床疗效。方法将晚期原发性肝癌60例,分为两组进行治疗:经导管肝动脉栓塞化疗(TACE)组30例(对照组);TACE联合CT引导下无水酒精注射及/或门静脉化疗,即三介入联合治疗组30例(联合治疗组)。观察两组间的生存率及门脉癌栓的消失率。结果对照组6、12、18、24个月生存率分别为56.7%(17/30)、40%(12/30)、20%(6/30)、6.7%(2/30),门脉癌栓消失率43.75%(7/16)。而治疗组6、12、18、24个月生存率分别为76.7%(23/30)、56.7%(17/30)、36.7%(11/30)、16.7%(5/30),门脉癌栓消失率为64.7%(11/17)。两组间生存率及门脉癌栓消失率均有统计学意义(P<0.05)。结论三介入联合治疗优于单纯栓塞化疗。
Objective To analyze the clinical efficacy of TACE, PEI and PVC in the treatment of advanced primary liver cancer. Methods Sixty patients with advanced primary liver cancer were divided into two groups: 30 patients underwent transcatheter arterial chemoembolization (TACE) group (control group), TACE combined with CT-guided anhydrous alcohol injection and / or portal vein chemotherapy Three involved in the combined treatment group of 30 patients (combination therapy group). Survival rate and disappearance rate of portal vein tumor thrombus were observed. Results The survival rates at 6, 12, 18 and 24 months in control group were 56.7% (17/30), 40% (12/30), 20% (6/30), 6.7% (2/30) Thrombus disappearance rate was 43.75% (7/16). The survival rates at 6, 12, 18, and 24 months in the treatment group were 76.7% (23/30), 56.7% (17/30), 36.7% (11/30), 16.7% (5/30) The rate of tumor thrombus disappearance was 64.7% (11/17). The survival rate and disappearance rate of portal vein tumor thrombus between the two groups were statistically significant (P <0.05). Conclusion Interventional combination therapy is superior to simple embolization chemotherapy.